340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma pushback pays off as HRSA requests additional public comment on key issues, including 340B ceiling prices and manufacturer civil monetary penalties.
You may also be interested in...
340B ‘Penny Pricing’ Policy Formally Adopted By HHS; Overcharging Safe Harbors Created
Final rule on 340B discounts also addresses how to handle pricing for new drugs.
340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.